Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets

References

• Vogler M, Hamali HA, Sun X-M, Bampton ETW, Dinsdale D, Snowden RT, Dyer MJS, Goodall AH, Cohen GM. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011;117:7145–7154. doi:https://doi.org/10.1182/blood-2011-03-344812.
   PubMed Web of Science ®Google Scholar
• Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, Josefsson EC, Alwis I, Ono A, Willcox A, et al. Bcl-x(L)-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663–1674. doi:https://doi.org/10.1182/blood-2011-04-347849.
   PubMed Web of Science ®Google Scholar
• Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173–1186. doi:https://doi.org/10.1016/j.cell.2007.01.037.
   PubMed Web of Science ®Google Scholar
• Wei H, Harper MT. ABT-737 triggers caspase-dependent inhibition of platelet procoagulant extracellular vesicle release during apoptosis and secondary necrosis in vitro. Thromb Haemost 2019;19:1665–1674. doi:https://doi.org/10.1055/s-0039-1693694.
   Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu Y-L, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149–1159. doi:https://doi.org/10.1016/S1470-2045(10)70261-8.
   PubMed Web of Science ®Google Scholar
• Souers A, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202–208. doi:https://doi.org/10.1038/nm.3048.
   PubMed Web of Science ®Google Scholar
• Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: A new wave in hematooncology. Exp Haematol 2018;61:10–25. doi:https://doi.org/10.1016/j.exphem.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang C-Y, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, et al. Structure-based design of potent small-molecule inhibitors of Anti-Apoptotic Bcl-2 Proteins. J Med Chem 2006;49:6139–6142. doi:https://doi.org/10.1021/jm060460o.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Mattera R, Sticca JI, Rossi P, Cipriani C, Giganti MG, Volpi A, Modesti A, Masuelli L, Bei R, et al. Effect of the BH3 Mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma. Front Pharmacol 2018;9:1269. doi:https://doi.org/10.3389/fphar.2018.01269.
   PubMed Web of Science ®Google Scholar
• Masuelli L, Benvenuto M, Izzi V, Zago E, Mattera R, Cerbelli B, Potenza V, Fazi S, Ciuffa S, Tresoldi I, et al. In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101. Invest New Drugs 2019. doi:https://doi.org/10.1007/s10637-019-00827-y.
   Google Scholar
• Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010;53:4166–4176. doi:https://doi.org/10.1021/jm1001265.
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res 2007;13:2226–2235. doi:https://doi.org/10.1158/1078-0432.CCR-06-1574.
   PubMed Web of Science ®Google Scholar
• Skommer J, Wlodkowic D, Mättö M, Eray M, Pelkonen J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res 2006;30:322–331. doi:https://doi.org/10.1016/j.leukres.2005.08.022.
   PubMed Web of Science ®Google Scholar
• Wang J-L, Liu D, Zhang Z-J, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci 2000;97:7124–7129. doi:https://doi.org/10.1073/pnas.97.13.7124.
   PubMed Web of Science ®Google Scholar
• Manero F, Gautier F, Gallenne T, Cauquil N, Grée D, Cartron P-F, Geneste O, Grée R, Vallette FM, Juin P, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006;66:2757–2764. doi:https://doi.org/10.1158/0008-5472.CAN-05-2097.
   PubMed Web of Science ®Google Scholar
• Wei H, Malcor J, Harper MT. Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets. Sci Rep 2018;8:9987. doi:https://doi.org/10.1038/s41598-018-28363-4.
   PubMed Web of Science ®Google Scholar
• van Kruchten R, Mattheij NJA, Saunders C, Feijge MAH, Swieringa F, Wolfs JLN, Collins PW, Heemskerk JWM, Bevers EM. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood 2013;121:1850–1857. doi:https://doi.org/10.1182/blood-2012-09-454314.
   PubMed Web of Science ®Google Scholar
• Choo H-J, Kholmukhamedov A, Zhou C, Jobe S. Inner mitochondrial membrane disruption links apoptotic and agonist-initiated phosphatidylserine externalization in platelets. Arterioscler Thromb Vasc Biol 2017;37:1503–1512. doi:https://doi.org/10.1161/ATVBAHA.117.309473.
   PubMed Web of Science ®Google Scholar
• Dekkers DWC, Comfurius P, Vuist WMJ, Billheimer JT, Dicker I, Weiss HJ, Zwaal RFA, Bevers EM. Impaired Ca2+-induced tyrosine phosphorylation and defective lipid scrambling in erythrocytes from a patient with Scott syndrome: A study using an inhibitor for scramblase that mimics the defect in Scott syndrome. Blood 1998;91:2133–2138. doi:https://doi.org/10.1182/blood.V91.6.2133.
   PubMed Web of Science ®Google Scholar
• Harper MT, Poole AW. Bcl-x(L)-inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores. Blood 2012;119:4337–4338. doi:https://doi.org/10.1182/blood-2012-02-413070.
   PubMed Web of Science ®Google Scholar
• Delbridge A, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 2015;22:1071–1080. doi:https://doi.org/10.1038/cdd.2015.50.
   PubMed Web of Science ®Google Scholar
• Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 2018;34:879–891. doi:https://doi.org/10.1016/j.ccell.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Eagle E. Chronic Toxicity of Gossypol. Science 1949;109:361. doi:https://doi.org/10.1126/science.109.2832.361.
   PubMed Web of Science ®Google Scholar
• Debrincat MA, Pleines I, Lebois M, Lane RM, Holmes ML, Corbin J, Vandenberg CJ, Alexander WS, Ng AP, Strasser A, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis 2015;6:e1721–e1721. doi:https://doi.org/10.1038/cddis.2015.97.
   PubMed Web of Science ®Google Scholar
• Kile B. The role of apoptosis in megakaryocytes and platelets. Br J Haematol 2014;165:217–226. doi:https://doi.org/10.1111/bjh.12757.
   PubMed Web of Science ®Google Scholar
• Millington-Burgess SL, Rahman T, Harper MT. R5421 is not a selective inhibitor of platelet phosphatidylserine exposure. OC 27.4 in Nurses and Orals Abstracts. Res Pract Thromb Haemost 2019;3:1–228. doi:https://doi.org/10.1002/rth2.12227.
   Google Scholar
• Gyulkhandanyan AV, Mutlu A, Allen DJ, Freedman J, Leytin V. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation. Thromb Res 2014;133:73–79. doi:https://doi.org/10.1016/j.thromres.2013.10.041.
   PubMed Web of Science ®Google Scholar
• Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJS, Cohen GM. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16:1030–1039. doi:https://doi.org/10.1038/cdd.2009.48.
   PubMed Web of Science ®Google Scholar
• Soderquist RS, Eastman A. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics. Mol Cancer Ther 2016;15:2011–2017. doi:https://doi.org/10.1158/1535-7163.MCT-16-0031.
   PubMed Web of Science ®Google Scholar
• Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM. Sabutoclax (BI97C1) and BI112D1, Putative inhibitors of MCL-1, Induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia 2013;15:568–IN22. doi:https://doi.org/10.1593/neo.13230.
   PubMed Web of Science ®Google Scholar
• Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ 2019;1–9. doi:https://doi.org/10.1038/s41418-019-0391-9.
   Google Scholar
• Bodur C, Basaga H. Bcl-2 Inhibitors: emerging drugs in cancer therapy. Curr Med Chem 2012;19:1804–1820. doi:https://doi.org/10.2174/092986712800099839.
   PubMed Web of Science ®Google Scholar
• Harper MT. Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload. Platelets 2019;30:98–104. doi:https://doi.org/10.1080/09537104.2017.1378809.
   PubMed Web of Science ®Google Scholar
• KIM E-J, LIM K-M, KIM K-Y, BAE O-N, NOH J-Y, CHUNG S-M, SHIN S, YUN Y-P, CHUNG J-H. Doxorubicin-induced platelet cytotoxicity: a new contributory factor for doxorubicin-mediated thrombocytopenia. J Thromb Haemost 2009;7:1172–1183. doi:https://doi.org/10.1111/jth.2009.7.issue-7.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Lim K-M, Noh J-Y, Kim K, Kang S, Chang YK, Shin S, Chung J-H Doxorubicin-Induced Platelet Procoagulant Activities: an Important Clue for Chemotherapy-Associated Thrombosis. Toxicol Sci 2011;124:215–224. doi:https://doi.org/10.1093/toxsci/kfr222.
   PubMed Web of Science ®Google Scholar
• Ma R, Bi Y, Kou J, Zhou J, Shi J. Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer. Cancer Biol Ther 2017;18:627–634. doi:https://doi.org/10.1080/15384047.2017.1345387.
   PubMedGoogle Scholar
• Zhang W, Zhao L, Liu J, Du J, Wang Z, Ruan C, Dai K. Cisplatin induces platelet apoptosis through the ERK signaling pathway. Thromb Res 2012;130:81–91. doi:https://doi.org/10.1016/j.thromres.2012.02.013.
   PubMed Web of Science ®Google Scholar